TY - JOUR
T1 - LEAP2 changes with body mass and food intake in humans and mice
AU - Mani, Bharath K.
AU - Puzziferri, Nancy
AU - He, Zhenyan
AU - Rodriguez, Juan A.
AU - Osborne-Lawrence, Sherri
AU - Metzger, Nathan P.
AU - Chhina, Navpreet
AU - Gaylinn, Bruce
AU - Thorner, Michael O.
AU - Louise Thomas, E.
AU - Bell, Jimmy D.
AU - Williams, Kevin W.
AU - Goldstone, Anthony P.
AU - Zigman, Jeffrey M.
N1 - Publisher Copyright:
© 2019, American Society for Clinical Investigation.
PY - 2019/9/3
Y1 - 2019/9/3
N2 - Acyl-ghrelin administration increases food intake, body weight, and blood glucose. In contrast, mice lacking ghrelin or ghrelin receptors (GHSRs) exhibit life-threatening hypoglycemia during starvation-like conditions, but do not consistently exhibit overt metabolic phenotypes when given ad libitum food access. These results, and findings of ghrelin resistance in obese states, imply nutritional state dependence of ghrelin's metabolic actions. Here, we hypothesized that liver-enriched antimicrobial peptide-2 (LEAP2), a recently characterized endogenous GHSR antagonist, blunts ghrelin action during obese states and postprandially. To test this hypothesis, we determined changes in plasma LEAP2 and acyl-ghrelin due to fasting, eating, obesity, Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), oral glucose administration, and type 1 diabetes mellitus (T1DM) using humans and/or mice. Our results suggest that plasma LEAP2 is regulated by metabolic status: its levels increased with body mass and blood glucose and decreased with fasting, RYGB, and in postprandial states following VSG. These changes were mostly opposite of those of acyl-ghrelin. Furthermore, using electrophysiology, we showed that LEAP2 both hyperpolarizes and prevents acyl-ghrelin from activating arcuate NPY neurons. We predict that the plasma LEAP2/acyl-ghrelin molar ratio may be a key determinant modulating acyl-ghrelin activity in response to body mass, feeding status, and blood glucose.
AB - Acyl-ghrelin administration increases food intake, body weight, and blood glucose. In contrast, mice lacking ghrelin or ghrelin receptors (GHSRs) exhibit life-threatening hypoglycemia during starvation-like conditions, but do not consistently exhibit overt metabolic phenotypes when given ad libitum food access. These results, and findings of ghrelin resistance in obese states, imply nutritional state dependence of ghrelin's metabolic actions. Here, we hypothesized that liver-enriched antimicrobial peptide-2 (LEAP2), a recently characterized endogenous GHSR antagonist, blunts ghrelin action during obese states and postprandially. To test this hypothesis, we determined changes in plasma LEAP2 and acyl-ghrelin due to fasting, eating, obesity, Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), oral glucose administration, and type 1 diabetes mellitus (T1DM) using humans and/or mice. Our results suggest that plasma LEAP2 is regulated by metabolic status: its levels increased with body mass and blood glucose and decreased with fasting, RYGB, and in postprandial states following VSG. These changes were mostly opposite of those of acyl-ghrelin. Furthermore, using electrophysiology, we showed that LEAP2 both hyperpolarizes and prevents acyl-ghrelin from activating arcuate NPY neurons. We predict that the plasma LEAP2/acyl-ghrelin molar ratio may be a key determinant modulating acyl-ghrelin activity in response to body mass, feeding status, and blood glucose.
UR - http://www.scopus.com/inward/record.url?scp=85071788917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071788917&partnerID=8YFLogxK
U2 - 10.1172/JCI125332
DO - 10.1172/JCI125332
M3 - Article
C2 - 31424424
AN - SCOPUS:85071788917
SN - 0021-9738
VL - 129
SP - 3909
EP - 3923
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 9
ER -